FDA Inspection 2026 Archives

News
Regulatory & Policy

Strides Pharma Receives USFDA EIR for Bengaluru Facility

Key Highlights: Implications: The USFDA’s EIR and VAI classification provide regulatory closure for Strides Pharma’s Bengaluru facility following the five observations issued during the May 2026 inspe...

Ridhi Rastogi

August 20, 2026

Browsing Tag: FDA Inspection 2026

Strides Pharma Receives USFDA EIR for Bengaluru Facility

Featured Posts

ChrysCapital to Acquire Stake in Linux Laboratories

Sanofi Partners with Tricog Health to Advance AI-Powered Cardiac Diagnostics

HRV Pharma to Invest ₹150 Crore to Expand Peptide and High-Potency API Capabilities